- Bio-Rad Laboratories, Inc. (BIO, BIO.B) has launched four new Droplet Digital PCR platforms.
- The expansion follows Bio-Rad's acquisition of Stilla Technologies, enhancing its product line.
- New platforms target genomics, oncology, infectious disease, and more.
Bio-Rad Laboratories, Inc. (BIO, BIO.B), a frontrunner in life science research and clinical diagnostics, recently announced a significant expansion of its Droplet Digital PCR (ddPCR) offerings. This move involves the launch of four new platforms, including the QX Continuum™ ddPCR system and the QX700™ series, stemming from the acquisition of digital PCR developer Stilla Technologies. Together, these platforms form a comprehensive portfolio aimed at advancing research and diagnostics in genomics, oncology, infectious diseases, and genetic applications.
The newly introduced systems join Bio-Rad's existing lineup, featuring industry-leading capabilities in absolute quantification and multiplexing, coupled with streamlined workflows. The QX Continuum™ system is particularly designed for translational research applications and offers a qPCR-like workflow with four-color multiplexing and multiple thermal profiles per plate.
The QX700™ series, comprising three new ddPCR instruments, focuses on academic research, environmental testing, and biopharma quality control, boasting seven-color multiplexing and significant sample processing capacity. Bio-Rad's strategic enhancement of its Droplet Digital PCR portfolio underscores its leadership in the genomics sector, offering high precision and flexibility for diverse scientific and commercial applications.
Jim Barry, EVP and President of Bio-Rad’s Life Science Group, emphasized that this expansion reinforces Bio-Rad's role in the genomics research and applied science markets, providing unparalleled workflow simplicity and throughput capabilities.
For further details on Bio-Rad's complete range of digital PCR products, visit their website at bio-rad.com/dropletdigitalPCR.
